was class 1A and the second tumor was class 2. While the first tumor had low metastatic risk, the second tumor had a higher risk of metastasis, demonstrating the importance of GEP testing in cases of multifocal disease.
cific gene expression profile (GEP) separates tumors into class 1 and class 2 tumors based on the results of a panel of 15 genes. Class 1A tumors have a 2% 5-year metastatic risk, while class 1B tumors have a 21% 5-year metastatic risk. Class 2 tumors have a 72% 5-year metastatic risk and are associated with high-risk clinical tumor features and genetic features such as monosomy 3, which are independent predictors of metastatic disease [5, 6] . The following case describes a patient with ocular melanocytosis who developed two sequential uveal melanomas that were found to be two different GEP tumor classes.
Case Report
A 53-year-old Caucasian male was found to have an asymptomatic choroidal tumor in the right eye (OD) on routine exam. He denied a personal or family history of cancer. On exam, bestcorrected visually acuity was 20/25 OD and 20/20 in the left eye (OS). Exam was notable for pigment in the angle, patchy blue-grey episcleral pigmentation, and a pigmented choroidal lesion located 3.0 mm superior to the optic nerve ( Fig. 1) , measuring 6.6 × 6.5 × 3.0 mm with overlying lipofuscin and associated subretinal fluid. A CT of the chest and abdomen was negative for metastasis. Two weeks later, the patient underwent fine needle aspirate (FNA) biopsy of the lesion and iodine-125 plaque brachytherapy. The bi- 238 opsy sample was sent to Castle Biosciences Incorporated (Phoenix, AZ, USA) for uveal melanoma-specific GEP testing for molecular prognostication. The DecisionDx ® -UMGenetic testing identified this tumor as a class 1A tumor. Follow-up studies showed a good response to treatment with atrophy of the tumor and subsequently stable size over visits. The patient developed secondary radiation retinopathy and a superior branch retinal vein occlusion, which were treated with posterior sub-Tenon's triamcinolone injections, bevacizumab intravitreal injections, and focal laser. He was followed on average four times per year without evidence of recurrence on exam.
On routine follow-up 4 years after the initial presentation, a second asymptomatic elevated pigmented choroidal lesion was identified along the distal inferotemporal arcade of the right eye (Fig. 1) . Best-corrected visually acuity was stable at 20/320. On ultrasound, the previously treated uveal melanoma appeared stable and the new tumor measured 10.0 × 10.0 × 3.5 mm (Fig. 2) . The tumor had overlying lipofuscin and associated subretinal fluid. Treatment options, including enucleation or placement of a second plaque, were discussed with the patient. Systemic testing was negative for metastasis. The patient subsequently underwent FNA biopsy of the new lesion and placement of an iodine-125 radioactive plaque. The biopsy sample was sent for GEP testing, which identified the new lesion as a class 2 tumor.
Discussion
Uveal melanoma is the most common primary malignant intraocular tumor in adults [7] and the incidence of uveal melanoma is highest among Caucasians [8] . While uncommon, the findings of bilateral uveal melanomas [9] [10] [11] [12] [13] [14] and multiple primary uveal melanomas in the same eye have been reported [2] [3] [4] . The congenital condition ocular melanocytosis, which is characterized by melanocytic hyperpigmentation of the episclera and uvea, has been associated with a 1 in 400 lifetime risk of developing uveal melanoma [1] . Patients with ocular melanocytosis, when compared to the general population, also have an increased risk of developing two isolated tumors in a single eye [2] . This was the case for our patient, who was noted to have diffuse unilateral grey-blue pigmentation of the episclera with the development of two distinct uveal melanomas separated by a period of 4 years.
Previously reported cases of multifocal unilateral ocular melanoma have relied on histopathological features to identify and differentiate tumors. Histopathological features alone can make it difficult to distinguish multiple de novo tumors from diffuse choroidal melanoma with multinodular, multifocal choroidal metastases or local recurrence of previously treated melanomas. More recently, genetic analysis has been used to further differentiate multiple uveal melanomas when they are localized to the same eye [3, 13] .
Our case is the first to use uveal melanoma-specific GEP testing on two primary uveal melanomas from the same eye. In our patient, genetic prognostic testing revealed the first tumor to be a class 1A and the second tumor to be a class 2 tumor. This suggests two separate de novo uveal melanomas, the first with low risk and the second with high risk of metastasis. This case demonstrates the importance of obtaining biopsies when there is concern for local recurrence or for a second primary tumor as the genetics and prognosis can differ. One caveat to these findings is that the FNA biopsy specimen was sent for GEP testing and molecular prognostication only and cytopathology was not performed. Without pa- thology of the globe we cannot definitively address whether this is a primary melanoma with persistent growth after treatment, a diffuse extension, or a second primary tumor. However, tumor locations, excellent first tumor response, close follow-up with rapid growth of second tumor, underlying ocular melanocytosis, and different GEP type all suggest a second primary tumor. Despite this drawback, the genetic testing for our patient proved critical for prognostication and will dictate the frequency and intensity of his follow-up and surveillance imaging going forward.
Statement of Ethics
All work presented here complies with the guidelines for human studies and animal welfare regulations. The review of medical records for publication of a single case report or a case series involving data from two or three patients is not considered by the Duke University Health System IRB to be research involving human subjects, and therefore such a report of medical cases does not require IRB review and approval.
Disclosure Statement
Miguel A. Materin, MD is a consultant for Castle Biosciences. None of the other authors on this paper have any conflicts of interest, sponsorship, or funding arrangements related to the case presented in the paper.
